Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3m4iOh4
via IFTTT